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Summary 
Herpes virus saimiri (HVS) immortalizes T  lymphocytes from a variety of primates and causes 
acute T  cell lymphomas and leukemias in nonnatural primate hosts. Here we have analyzed the 
requirements for growth of three HVS-transformed human T  cell lines.  The cells expressed the 
phenotype of activated T cells: two were CD4 + , and one was CD8 + . All three cells responded 
to all allogeneic human cell lines tested with enhanced proliferation,  production of interleukin 
2 (Ib2), and increased expression of the I1:2 receptor. Binding of CD2 to its ligand CD58 was 
the critical event mediating stimulation because: (a) monoclonal antibodies (mAbs) to CD2 and 
to CD58, but not  to a variety of other  surface structures,  blocked induced  and spontaneous 
proliferation and Ib2 production; (b) only anti-CD2 mAbs were stimulatory if crosslinked; (c) 
a nonstimulatory cell was rendered stimulatory by CD58 transfection; and (d) the cells responded 
specifically  to CD58 on sheep red blood cells.  Growth of the cells required activation because 
cyclosporin A and FK506 blocked stimulator cell-induced II:2 production and proliferation as 
well as the spontaneous growth of the lines. Antibodies to the I1:2 receptor reduced proliferation 
of the cells and blocked 11:2 utilization. Taken together, these results show that HVS-transformed 
T cells proliferate in response to CD2-mediated contact with stimulator cells or with each other 
in an I1:2-dependent fashion. They suggest that HVS transforms human T cells to an activation- 
dependent  autocrine  growth. 
H 
erpes virus saimiri (HVS) is the prototype of the lym- 
photropic 3~-2 herpes viruses (rhadinoviruses). Natural 
hosts of the virus are the squirrel monkeys (Saimiri sciureus). 
By cocultivation with permissive monolayer cells, HVS can 
be isolated from PBL >80% of the population,  and at least 
one in 106 T  cells will yield virus (reviewed in reference 1). 
The virus persists in T  cells for their lifetime.  HVS is not 
pathogenic for squirrel monkeys, even after immunosuppres- 
sion. In contrast to this benign behavior in its natural host, 
HVS has a high oncogenic potential in numerous other New 
World primates (1). It causes acute lymphoproliferative syn- 
dromes,  leukemias,  and  lymphomas.  After  infection,  the 
animals die within a few weeks from rapidly progressing ne- 
oplasias.  Cell lines can be established from infected animals 
that initially produce virus in "~1-10% of the cells, but after 
prolonged cultivation the ability to produce virus is lost (2), 
HVS is able to transform T lymphoeytes of nonhuman pri- 
mates as well as human PBL and thymocytes to continuous 
growth (2, 3). The molecular basis of T cell stimulation and 
transformation  is unknown. 
In this study we show that transformation with HVS in- 
duces human T cells to respond to cell-cell contact with each 
other and with other cells leading to I1:2-dependent  auto- 
crine growth. The critical stimulating signal in this contact 
is given by binding of the CD2 molecule to its natural ligand. 
These HVS-transformed T  cells are the first example of an 
activation-dependent growth of transformed cells and could 
be a valuable model for viral oncogenesis. 
Materials  and Methods 
Cells.  HVS-transformed human T cell lines were initiated by 
infection with the 488 strain that belongs to subgroup C of HVS 
as described (3). Three different lines were used in this study: V20 
and V25 are CD4 + subclones of a CD4 + T cell line derived from 
adult PBMC, CB15 is a CD4 + cell line derived from cord blood 
lymphocytes, and P1084 is a CD8 + clone derived from thymo- 
cytes. These lines had been in culture for 6-12 mo when the ex- 
periments  described here were performed. 
Clones of normal human T cells of CD4 + or CD8 + phenotype 
were generated and propagated as described (4). Several  established 
tumor cells were used as stimulator cells: the Burkitt's lymphoma 
Raji and its MHC class II-negative mutant RJ.225 (5); the L428 
cells derived from Hodgkiffs disease that are HLA class I negative, 
class II positive, CDll/CD18 negative, and express large amounts 
of CD58; several different EBV-transformed B cells; and the fol- 
lowing mouse cell lines: the mastocytoma P815, the plasmocytoma 
909  J. Exp. Med. ￿9  The Rockefeller  University Press ￿9 0022-1007/92/09/0909/05 $2.00 
Volume 176  September  1992  909-913 Table  1.  Response of HVS-transformed Cells to Allogeneic and Xenogeneic Cells 
Response of V20 cells  Response of P1084 cells 
Stimulus  Proliferation  IL-2 production  Proliferation  IL-2 production 
Medium  1,300  <0.1  7,000  <0.1 
Raji  27,600  4.1  26,500  10.2 
RJ.225  10,300  2.9  26,300  8.3 
L428  20,400  11.5  30,600  11.6 
EBV + B cell  17,100  3.2  16,800  4.3 
A20/J  3,600  <0.1  8,000  <0.1 
A20-D45  3,300  <0.1  7,000  <0.1 
A20-P24  17,800  3.6  16,100  5.4 
P3X63  5,600  <0.1  10,600  ND 
P815  3,000  0.2  11,400  <0.1 
V20 cells (CD4  +) and P8014 (CD8  +) cells were stimulated  with allogeneic  or xenogeneic  mitomycin  C-treated cells, and proliferation  (cpm incor- 
porated into responder ceils) and IL-2 production (units IL-2/ml culture supernatant) were measured. 
P3X63Ag8, the macrophage line P338D1, and B cell lymphoma 
A20/J, and two derivatives:  a DtL3-transfected  subline (A20-D45) 
and a CD58-transfected subline (A20-P24; reference 6). 
Reagents.  The following mAbs were used: three mAbs against 
CD58 (LFA-3): TS2/9 specific  for human CD58 (7), L180/1 specific 
for the sheep homologue of CD58 (8), and AICD58.3 recognizing 
both human and sheep CD58.  Three mAbs against the SRBC- 
binding Tl1-1 epitope of CD2:CB.219 (4), OKTll, and GT2, as 
well as mAb D66 against CD2R (7, 9, 10). OKT3 against CD3; 
BMA031 against the TCR oe/3; MT151, MT321, and BMA041 
against CD4; MT 61 against CD5; and BMA081 against CD8 (7). 
Also used were anti-Tac (11) against the 55-kD chain of the ID2 
receptor, TS1/22 against CD11a, 7F7 against the intercellular  adhe- 
sion molecule 1 CD54 (10), W6/32 against HLA dass I antigens, 
L243 against HLA-DR, CLB.CD28 against CD28 (10), and BB.1 
against the CD28 ligand B7 (12). 
Assays for Proliferative Activity and 11.2 Production.  Proliferative 
responses were measured in triplicates of 200 #1 containing 2-3 
x  104 T cells as responders and 3  x  104 mitomycin C-treated 
tumor  cells as  stimulator  calls (4). Assays were pulsed with 
[3H]thymidine after 24  h  for  16  h.  For determination of Ib2 
production, supernatants of such cultures were harvested  after 24 h 
and assayed for Ib2 using CTLIr  cells. 
Results 
Response of  HVS-transformed T Cells to Allogeneic Cells.  The 
three cell lines expressed the phenotype of activated T cells. 
They were CD2 +, CD3 +, TCR c~/B +, and expressed  the 
IL-2 receptor (p55,  CD25),  CD26,  CD58,  and HLA class 
II  molecules.  The  CD4 +  cell  lines  were  CD28 +.  The 
growth of the CD4 + cells slowed down in the absence of 
added IL-2 but the cells survived several weeks, whereas the 
CD8 + cell line stopped growing when II.-2 was removed 
from the culture medium and died within a few days. The 
cells grew best at high densities, and cell growth decreased 
or stopped if the cells were seeded  at low density. 
The HVS-transformed cells responded to allogeneic human 
stimulator cells alone with increased  proliferation and IL-2 
production (Table 1). Spontaneously, there was little or no 
secretion of I1.-2 detectable,  but strong IL-2 production was 
found in the presence of all human cell lines tested. It is evi- 
dent from the phenotype of the stimulator cells used that 
this stimulatory activity for both CD4 + and CD8 + cells 
Table 2.  Stimulation  of  lL-2 Production in HVS-transformed T Cells 
IL-2 production by 
CB15 cells with: 
mAb added  Specificity  L428  A20/J 
None  6.2  0.1 
CB.219  CD2 (IgG2b)  <0.1  3.5 
OKT3  CD3 (IgG2a)  6.4  0.2 
BMA031  TCRccj8 (IgG2b)  7.1  0.1 
BMA041  CD4  (IgM)  5.6  0.1 
M-T151  CD4 (IgG2a)  4.9  <0.1 
M-T321  CD4 (IgG1)  6.9  0.1 
M-T61  CD5  (IgG1)  6.0  0.1 
CLB.CD28  CD28 (IgG1)  6,7  0.1 
TS1/22  CDlla (IgG1)  7.3  <0.1 
TS2/9  CD58  (IgG1)  <0.1  <0.1 
W6/32  class I (IgG2a)  8.4  0.1 
L243  HLA-DR (IgG2a)  7.0  0.1 
CB15 cells stimuhted with L428 or A20/J cells in the presence of the 
mAb indicated (1/~g/ml or 1:1,000 dilution of ascitic fluid). Superna- 
tants were assayed for IL-2 after 24 h. Data are units IL-2/ml. 
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Require Activation 
Proliferation*  Expression otis 
Production 
Additions  - IL-2  + IL-2  of IL-2*  CD25  HLA-DR 
Medium  6,000  13,600  <0.1  480  580 
CyA  200  6,300  <0.1  350  430 
Raji  32,100  30,300  14  550  510 
Raji  +  CyA  2,400  6,900  <0.1  370  440 
Figure  1.  Response  to SR.BC of HVS-transformed  cells is especially 
inhibited by mAbs to sheep CD58. CB15 cells were incubated in fiat- 
bottomed  wells  with  SRBC (0.25%; vol/ml)  or L428  cells  and mAb CB.219 
(anti-CD2), L180/1 (anti-sheep CD58), TS2/9 (anti-human  CD58), or 
AICD58.3 (anti-sheep and -human CD58). 
was not dependent on the presence  of HLA class I or dass 
II molecules. Fixation with glutaraldehyde did not decrease 
the stimulating capacities of allogeneic cells, indicating that 
a secreted product of the stimulating cells did not play a role 
(not shown). Several routine cell lines, some of them shown 
in Table 1, did not induce enhanced proliferation and Ib2 
secretion or were only very weak stimulators. Interestingly, 
the CD58-transfected A20-P24 cells, but neither the parental 
A20/J cells nor the HLA-DR3-transfected A20/J cells, had 
stimulatory capacity for all three HVS-transformed T cells. 
Cell Su~ace Molecules Involved in Stimulation.  To see which 
cell surface structures were involved in the stimulating reac- 
tion, we used several mAbs to block triggering of prolifera- 
tion and IL-2 production. Table 2 shows a typical experiment 
with CB15  (CD4 +)  responder cells  and L428 and A20/J 
cells as stimulators. The only mAbs that completely inhibited 
the response to L428 ceils were those to CD2 and its ligand 
CD58. mAbs to CD3 and the TCR did not block stimula- 
tion significantly, and several anti-CD4 mAbs and TS1/22 
to CDlla only sometimes showed slight inhibition. Although 
not shown here,  the 7F7 mAb to CD54, the BB.1 mAb to 
the CD28 ligand B7, and several anti-class II mAbs did not 
inhibit. There was also no influence of mAb D66 directed 
against a restricted stimulating epitope on CD2 not involved 
in SRBC binding (not shown). Noteworthy, only antibodies 
to CD2 and CD58 blocked spontaneous II.-2 production and 
reduced spontaneous proliferation (data not shown). 
The three anti-CD2 mAbs directed against the Tll-1 epi- 
tope were able to induce Ib2 production (as shown for CB.219 
in Table 2) and enhanced proliferation (not shown) if cross- 
linked by the nonstimulating A20/J cells that are Fc receptor 
positive.  In contrast, all  other antibodies, including D66, 
OKT3, BMA031, and CLB.CD28, did not induce significant 
IL-2 secretion. 
To directly assess the role of CD58  in this stimulation, 
we used SRBC as stimulators and two mAbs that discriminate 
between human and sheep CD58. Indeed, incubation of HVS- 
V25 cells were incubated  with various additions  for 2 d, whereafter  the 
cells were pulsed with [3H]thymidine  for 24 h. IL-2  production  was as- 
sayed  in parallel  cultures  after  24 h of incubation.  The expression  of CD25 
and HLA-DR molecules  was determined after incubation of 5  ￿  10  s 
cells/ml for 4 d with the additions indicated. 
* cpm incorporated by V25 cells 
* Units IL-2/ml supernatant 
S  Mean channel  fluorescence  intensity  (FACScan~ Staining  with a nega- 
tive control mAb gave an intensity  of 100, staining  with OKT3 mAb 
gave an intensity  of 660-680 irrespective of treatment. 
transformed cells with SRBC stimulated II.,2 production (Fig. 
1) and enhanced proliferation (not shown). This stimulation 
was completely abrogated by anti-CD2 mAbs and by the mAb 
L180/1 to sheep CD58 but not by TS2/9 to the CD58 ex- 
pressed  by the responder cells. 
11_,2 Production and 11.2 Receptor Expression Require Activa- 
tion.  To obtain further evidence that proliferation and Ib2 
production were triggered via pathways involved in normal 
T cell activation, we used the immunosuppressants  cyclosporin 
A (CyA) and FKS06, which interfere with T cell signal trans- 
duction.  Both  compounds inhibited II.,2  production  and 
proliferation induced by allogenic cells in CD4 + and CD8 + 
HVS-transformed cells. This is shown in Table 3 for CyA 
and the response  of V25 cells. The concentrations required 
were the same that were effective in normal human T  cell 
clones. 
Moreover,  CyA treatment could downregulate the IL-2 
receptor on HVS-transformed ceils. When the cells were in- 
cubated for 4 d in 1/zg/ml CyA, they became smaller and 
resembled resting T  cells. As shown in Table 3, the expres- 
sion of the 55-kD chain of the I1.-2 receptor (CD25) and of 
HLA class II molecules on these cells decreased.  If untreated 
HVS-transformed cells were incubated with Raji cells, an en- 
hancement of CD25 expression was seen that could be blocked 
by CyA (Table 3). Noteworthy also, the response to II:2 was 
reduced by CyA. In addition, in the presence of CyA, V20, 
V25, and P1084 cells stopped growing even in the presence 
of II..2.  Identical findings were made with FK506 at  100- 
fold lower concentrations. Taken together, this indicates that 
the activated phenotype of the cells was due to the perma- 
nent reception of activation signals. 
Evidence.for Autocrine Growth.  Because production of and 
response  to IL-2 appeared  to depend on permanent stimula- 
tion, we investigated if HVS-transformed T cells would grow 
in an IL-2-dependent autocrine fashion. In the absence of stimu- 
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Proliferative response of: 
P1084 cells  V20 cells 
Stimulus  Medium  Anti-Tac  Inhibition  Medium  Anti-Tac  Inhibition 
Medium  18,000  11,000  39%  1,700  1,200  30% 
L428 cells  40,000  42,000  0%  37,500  37,300  0% 
IL-2  25,000  18,000  28%  25,200  3,600  86% 
HVS-transformed  cells were incubated with L428 cells or 20 U/ml of rlL-2, and their proliferation  was assayed after 48 h. Data are given as cpm 
[3H]thymidine incorporated  and percent  inhibition by anti-Tac. 
lator cells, HVS-transformed cells proliferated but Ib2 was 
not or in only low amounts detectable in the supernatant. 
Addition of exogenous IL-2 enhanced proliferation and anti- 
Tac mAb inhibited spontaneous and Ib2-induced but not 
stimulator cell-induced proliferation of V20, V25, and the 
CD8 + cells in short-term assays. Such an experiment with 
the P1084 CD8 + and the V20 CD4 + cell lines is shown in 
Table 4. CB15 cells were less sensitive to anti-Tac (not shown). 
Furthermore, anti-Tac mAb was able to increase the concen- 
tration of IL-2 in the supernatant of all three cell lines, with 
both  CD4 +  and  CD8 +,  indicating  that  anti-Tac blocked 
utilization of Ib2  (data not shown). 
Discussion 
This report describes three independent lines of HSV-trans- 
formed human T  lymphocytes. The three cell lines express 
the phenotype of activated T cells and possess the functional 
capacities of normal T lymphocytes: a proliferative response, 
lymphokine secretion, and induction of IL-2 receptors. 
A common characteristic of these cells is their response 
to allogeneic stimulator cells. Apparently, any allogeneic cell, 
regardless of HLA class I or II expression, can stimulate HVS- 
transformed cells. This argues against the recognition of a 
superantigen or of a promiscuous peptide on the stimulator 
cells.  Rather, the stimulating signal appears  to be given by 
binding of the CD2 molecule to its natural ligand. The evi- 
dence for this notion is provided by the selective inhibition 
of stimulation by anti-CD2 and anti-CD58 mAbs, the po- 
tent stimulatory activity of mAbs directed against the ligand 
binding site of CD2, and, most notably, the response to SRBC 
and to CD58 transfectants. The response to SRBC suggests 
that the CD58  molecules is stimulatory in the absence of 
other ligands for T cell surface structures. That several mouse 
cells were not or only weakly stimulatory is probably due 
to the inefficient interaction of human CD2 with mouse CD58 
(6), in contrast to human CDlla/CD18, which binds mouse 
intercellular adhesion molecule 1 efficiently (13). HVS-trans- 
formed cells are the only example showing that binding of 
CD2 to its natural ligand alone is sufficient to activate a T 
cell. mAbs to restricted sites of the CD2 molecule, such as 
D66 or Tl13,  have been shown to activate T  cells if com- 
bined with mAbs to the ligand binding site or the ligand 
itself (9,  14). However, the general relevance of this type of 
stimulation is still unclear. Such a mAb (D66) was not stimula- 
tory for HVS-transformed cells, but rather inhibited the ac- 
tivation via the anti-CD2 mAb CB.219  (not shown). Sur- 
prisingly, mAbs to CD3 or to the TCR did not or only weakly 
induced IL-2 production and enhanced proliferation with Fc 
receptor-bearing accessory cells and did not inhibit the re- 
sponse to allogeneic cells. This is in striking contrast to the 
behavior of normal human T cells, which are stimulated by 
mAbs to the CD3/TCR complex but not by the anti-CD2 
mAbs. This could indicate that CD2 constitutes an indepen- 
dent pathway in the herpes virus-transformed cells that is 
uncoupled from TCR/CD3  signaling. 
Our data strongly suggest that this interaction of CD2 
with CD58 during mutual cell-cell contact is the signal leading 
to autocrine growth of HVS-transformed cells. Most notably, 
incubation of the cells with anti-CD2 or anti-CD58 mAbs 
reduced growth of the cells. The findings with CyA and FK506 
also  support  the  notion  that  the  growth  of the  HVS- 
transformed cells is due to the permanent reception of ac- 
tivating signals  during cell-cell contact. These compounds 
inhibited  IL-2 production  as  well  as  growth  of  HVS- 
transformed cells. The experiments with anti-Tac suggest that 
IL-2-mediated growth was the principle governing the growth 
of the V20 and the CD8 + cells. That anti-Tac mAb did not 
inhibit optimally stimulated cells is also found with some 
normal human T cell clones (data not shown) and could be 
due to an excess production and short-range action of Ib2 (11). 
In spite of these common mechanisms of responses the three 
cell lines had different growth characteristics. The CD4 + 
V20 and V25 subdones and the CD8 + P1084 line had a low 
spontaneous background proliferation and responded with 
strongly enhanced proliferation to stimulator cells. These cells 
required exogenous Ib2 for growth and survival if they were 
cultured at low density. In contrast,  the CB15  cells had a 
high background proliferation that usually was >50% of the 
maximal response. This line grew in the absence of exoge- 
nous Ib2 and, if supplied with IL-2, was only poorly inhibited 
in its growth by CyA. Thus,  the CB15 ceils appear to be 
more autonomous than the other cell lines,  possibly at an 
advanced stage of transformation. These properties of the ceils 
912  Herpes Virus Saimiri-transformed T  Cells were stable within the observation period. It is noteworthy 
that  the CB15 cell line had been initially established in the 
absence of exogenous IL-2. 
Autocrine growth factor production is a recognized mech- 
anism of autonomous growth (15).  So far,  however, in the 
reported examples the respective growth factor is produced 
constitutively.  Transfection of a growth  factor into  factor- 
dependent cells leads to autonomous proliferation and tumor- 
igenicity in vivo (15). The HVS-transformed cells are the first 
example of an autocrine growth of transformed  cells with 
an  activation  signal-dependent  growth  factor production. 
Only two other cells have been reported that show a similar 
behavior. A  human T  cell leukemia cell was described that 
expressed 1I,-2 receptors, produced IL-2, and proliferated au- 
tonomously at high cell densities only (16).  Growth of the 
cells was inhibited by CyA (17). In addition,  a recent report 
showed that the IIA-dependent growth of RadLV-transformed 
murine T  cells is sensitive to CyA (18).  This could indicate 
that similar, although still uncharacterized, activation-depen- 
dent  mechanisms  are operating  in  these cells. 
In summary, our results suggest that HVS-transformed T 
cells grow via an autocrine mechanism, in response to activa- 
tion  signals given by their CD2 molecules during  mutual 
cell-cell  contact.  These  cells  are  the  first  example  of an 
activation-dependent autocrine growth and will be a prom- 
ising  model for viral oncogenesis. 
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